IP Library Granted Patent US 10,278,961
Granted Patent B2
US 10,278,961 · App. 15/491,933 · Granted May 7, 2019

Administration of berberine metabolites

Inventors: Ryan Lowery (Tampa, FL); Jacob Wilson (Tampa, FL); Shawn Wells (Lewisville, TX); Terry LaCore (Melissa, TX)
Assignee: Keto Patent Group, Inc.
A61K31/4355A61K9/0095A61K38/005A61K47/544A61K9/1075
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,278,961
App. No.
15/491,933
Granted
May 7, 2019
Kind
B2
Abstract

In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.

Claims (22)

1. A method of managing glucose tolerance in an individual, the method comprising:

administering, to an individual, a pharmaceutically effective amount of dihydroberberine, wherein the pharmaceutically effective amount of dihydroberberine comprises approximately 25 mg to approximately 800 mg of dihydroberberine.

2. The method of claim 1 wherein the administration of dihydroberberine reduces fasting glucose levels.

3. The method of claim 1 wherein the dihydroberberine is administered as a complexed composition, and wherein the complexed composition further comprises at least one of complexed phytosomes or liposomes.

4. The method of claim 1 wherein the dihydroberberine is a microemulsion including dihydroberberine.

5. The method of claim 1 wherein the dihydroberberine is orally administered as a capsule or tablet.

6. The method of claim 1 wherein the dihydroberberine is orally administered as at least one of a food product or beverage product.

7. The method of claim 1 wherein the dihydroberberine is administered at least once daily.

8. The method of claim 1 further comprising administrating a Cytochrome P450 inhibitor, wherein administration of the Cyctochrome P450 inhibitor allows decreasing of the amount of dihydroberberine administered to be sufficient to achieve the desired results.

9. A method of increasing blood ketone levels in an individual, the method comprising:

administering, to an individual, a pharmaceutically effective amount of dihydroberberine, wherein the pharmaceutically effective amount of dihydroberberine comprises approximately 25 mg to approximately 800 mg of dihydroberberine.

10. The method of claim 9 wherein the dihydroberberine is administered approximately concurrently with meals.

11. The method of claim 9 further comprising administrating, to the individual, a pharmaceutically effective amount of one or more additional compounds capable of independently increasing blood ketone levels.

12. The method of claim 11 wherein the dihydroberberine and at least one of the additional compounds are administered approximately concurrently.

13. The method of claim 11 wherein the dihydroberberine and one or more of the additional compounds are administered at least one time daily.

14. The method of claim 9 wherein the pharmaceutically effective amount of dihydroberberine is administered with one or more additional compounds, and wherein one or more of the additional compounds comprises at least one of a beta-hydroxybutyrate, butyrate, a fatty acid, or ester of fatty acid, and wherein the amount of dihydroberberine administered to be pharmaceutically effective is less than the amount of dihydroberberine administered to be pharmaceutically effective when the dihydroberberine is administered without at least one of the additional compounds.

15. The method of claim 14 wherein at least one of the additional compounds comprises a R-beta-hydroxybutyrate compound.

16. The method of claim 14 wherein one or more of the additional compounds comprises at least one of a beta-hydroxybutyrate salt or beta-hydroxybutyrate polymer.

17. The method of claim 14 wherein the dihydroberberine and at least one of the additional compounds are administered approximately concurrently.

18. The method of claim 14 wherein the composition comprises at least two of the additional compounds, and wherein two or more of the additional compounds comprises a beta-hydroxybutyrate and at least one of a fatty acid or ester of a fatty acid.

19. The method of claim 1 wherein the pharmaceutically effective amount of dihydroberberine is administered with one or more additional compounds, and wherein one or more of the additional compounds comprises at least one of a beta-hydroxybutyrate, butyrate, a fatty acid, or ester of fatty acid.

20. The method of claim 9 wherein the pharmaceutically effective amount of dihydroberberine is administered with a beta-hydroxybutyrate and a medium chain fatty acid.

Assignments (3)
NUNC PRO TUNC ASSIGNMENT Recorded Jan 24, 2025
From: WELLS, SHAWN
To: NANJING NUTRABUILDING BIO-TECH CO., LTD.
Reel/Frame 069997/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2021
From: KETO PATENT GROUP, INC.
To: NANJING NUTRABUILDING BIO-TECH CO., LTD.
Reel/Frame 058348/0477 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2019
From: LACORE, TERRY; LOWERY, RYAN; WILSON, JACOB
To: KETO PATENT GROUP
Reel/Frame 048709/0467 →
Continuity (2)
Provisional Application 62324794 · Apr 19, 2016
Related Publication 20170296520A1 · Oct 19, 2017
Cited By (10)
US 12,251,362 US 12,329,734 US 12,350,243 US 12,458,631 US 12,496,283 US 12,521,378 US 12,533,331 US 12,533,346 US 12,599,579 US 12,622,889